Research conducted at the Lady Davis Institute provides proof of concept that an existing drug holds promise for reversing loss of memory and brain lesions associated with Alzheimer disease.
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.
For years, Dr. Andréa LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss. Her team discovered that the Caspase-6 enzyme is highly activated in Alzheimer disease brain lesions and associated with loss of memory. She, therefore, pursued the hypothesis that stopping Caspase-6 might provide relief from memory loss and stop progressive dementia. Since there are no specific Caspase-6 inhibitors, the LeBlanc team moved upstream, ultimately discovering that Caspase-1 was responsible for activating Caspase-6.
“This was a significant revelation because Caspase-1 inhibitors had been developed for treating inflammatory diseases,” explains Dr. LeBlanc. “Thus, we decided to test the effects of a particular Caspase-1 inhibitor, called VX-765, against memory loss and brain pathologies in a mouse model of Alzheimer disease.”
The work, first authored by Dr. Joseph Flores, a research associate in the LeBlanc lab, showed that VX-765 has an unprecedented beneficial effect in Alzheimer mice. The drug rapidly reverses memory loss, eliminates inflammation, and stops Alzheimer’s prototypical amyloid peptide accumulation in the mice brains. In addition to being safe for humans at relatively high doses for extended periods of time, it is capable of reaching the brain, a significant challenge in the development of drugs against disorders of the brain.
While Dr. LeBlanc cautions that there is a considerable bridge to cross between the mouse brain and that of a human, she believes that since her work has first identified the Caspase-1/Caspase-6 neurodegenerative pathway in human neurons and in human Alzheimer brains, there is a chance that this drug will work just as well in humans as it did in mice. Nevertheless, a clinical trial is needed to determine whether the drug will be beneficial against Alzheimer disease in humans.
Presently, there are no efficient treatments to significantly treat Alzheimer disease, the major affliction in a group of dementias that affect 47.5 million individuals worldwide.
Receive an email update when we add a new ALZHEIMER’S article.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Alzheimers Q & A: Is a diagnosis of Alzheimer's disease or dementia becoming more common? on November 11, 2018 at 3:21 pm
According to a Duke University study, population health scientists have described Alzheimer's disease as both decreasing and increasing in prevalence. The confusion, it seems, stems from the difficult... […]
- La Crosse students research aging, Alzheimers on November 9, 2018 at 8:53 pm
LA CROSSE, Wis. (WSAW) --Students at UW-La Crosse are conducting special research that could affect the future of medical research for aging. They're using space in the Prairie Springs science center ... […]
- Dame Barbara Windsor tap dances in rare public appearance since Alzheimers diagnosis on November 8, 2018 at 7:36 pm
The 81-year-old was at the theatre to see pal Bonnie Langford perform in 42nd Street The Musical The 81-year-old EastEnders star was at the Theatre Royal Drury lane to see pal Bonnie Langford perform ... […]
- Therapy that Dramatically Slows Alzheimers has Passed Final Clinical Phase on November 6, 2018 at 11:25 am
Through a new approach dubbed AMBAR, the biotechnology company Grifols has attempted to reduce the amount of harmful, Alzheimer’s disease-causing amyloid beta in the brain by collecting it with a bloo... […]
- Healthy Mind: The Caregivers' Club film and Alzheimers panel at Cinema du Parc Nov. 8th on November 5, 2018 at 7:00 am
Carrefour Productions Inc. recently announced in a press release the Quebec premiere of the documentary The Caregivers’ Club, directed by award-winning filmmaker Cynthia Banks. The special event is be... […]
- Alzheimers Q&A: Why is November known as National Alzheimer's Disease Awareness month? on November 4, 2018 at 4:20 pm
After gaining an understanding of how Alzheimer's disease impacts people, President Ronald Reagan determined it was important enough to raise awareness of this devastating condition and so in 1983, he ... […]
- Deputies searching for missing man with Alzheimers in Greenville on November 4, 2018 at 1:28 am
GREENVILLE, SC (WSPA) - Greenville County Deputies are asking for help to find a missing 72-year-old man. Deputies say Joseph Taylor was last seen around 10 pm Saturday night on Roper Mountain Road. T... […]
- Missing man with Alzheimers found safe, Greenville Co. deputies say on November 4, 2018 at 1:28 am
GREENVILLE, S.C. (WSPA) - UPDATE (11/4/18 11:20 a.m.): The Greenville County Sheriff's Office confirmed that Joseph Christopher Taylor has been located safely. Deputies said a man noticed Taylor walki... […]
- Global Alzheimers Disease (AD) Diagnostics and Therapeutics Market 2018- Growth, Industry Demand, Trends, Forecast To 2023 on November 1, 2018 at 3:14 am
The Global Alzheimer’s diagnostics and therapeutics market was valued at approximately USD 7,100 million for 2017 and is expected to register a CAGR of approximately 6.7% during the forecast ... […]
via Bing News